Acute Intermittent Porphyria Market Report 2026

Acute Intermittent Porphyria Market Overview

• Acute Intermittent Porphyria market size has reached to $4.66 billion in 2025 • Expected to grow to $6.33 billion in 2030 at a compound annual growth rate (CAGR) of 6.2% • Growth Driver: Impact Of Rising Metabolic Disorders On The Growth Of The Acute Intermittent Porphyria Market • Market Trend: Innovations In Acute Intermittent Porphyria Management • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Acute Intermittent Porphyria Market?

Acute intermittent porphyria (AIP) is a rare genetic disorder that affects the production of heme, a vital component of hemoglobin in the blood. AIP is characterized by intermittent attacks of severe abdominal pain, gastrointestinal disturbances, and neurological symptoms, including muscle weakness, seizures, and mental changes such as anxiety, confusion, or hallucinations. The main acute intermittent porphyria diagnoses include urine tests, blood tests, serum tests, DNA tests, and others. The urine test method involves analyzing a sample of urine to detect elevated levels of porphyrins or their precursors, which are indicators of acute intermittent porphyria (AIP). It offers various types of treatments, such as prophylactic hematin infusions, gonadotropin-releasing hormone analogues, and others, and it is used by hospitals and clinics, ambulatory surgical centers, and research centers.

What Is The Acute Intermittent Porphyria Market Growth Forecast?

The acute intermittent porphyria market size is expected to see strong growth in the next few years. It will grow to $6.33 billion in 2030 at a compound annual growth rate (CAGR) of 6.2%. The growth in the forecast period can be attributed to development of novel therapies and hematin formulations, expansion of dna and enzyme testing services, increasing integration of telemedicine for rare diseases, rising awareness and educational programs for healthcare providers, adoption of advanced monitoring and digital health tools. Major trends in the forecast period include increased adoption of genetic and enzyme-based diagnostic tests, rising awareness about early diagnosis and management of aip, growth in prophylactic hematin infusions and targeted therapies, expansion of specialized treatment centers and research programs, integration of telemedicine and remote patient monitoring for aip patients.

What Is The Driver Of The Acute Intermittent Porphyria Market?

The prevalence of metabolic disorders is expected to propel the growth of the acute intermittent porphyria market going forward. Metabolic disorders are a group of conditions that occur due to abnormal chemical reactions in the body that disrupt the normal process of metabolism. The prevalence of metabolic disorders is due to genetic factors, lifestyle factors, environmental influences, and increased awareness and diagnosis. The rise in metabolic disorders is encouraging the pharmaceutical industry to invest in treatments for rare and genetic conditions such as acute intermittent porphyria. For instance, in December 2023, according to Cleveland Clinic, a US-based nonprofit academic medical center, inherited metabolic disorders collectively impact approximately 1 in 1,000 to 2,500 births worldwide. Therefore, the prevalence of metabolic disorders is driving the growth of the acute intermittent porphyria industry.

Key Players In The Global Acute Intermittent Porphyria Market

Major companies operating in the acute intermittent porphyria market are Pfizer Inc., Johnson & Johnson, Roche Holding AG, Merck & Co. Inc., AbbVie Inc., Sanofi SA, AstraZeneca Plc, Novartis AG, GlaxoSmithKline Plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Gilead Sciences Inc., Amgen Inc., Novo Nordisk A/S, Regeneron Pharmaceuticals Inc., Daiichi Sankyo Company Limited, Vertex Pharmaceuticals Inc., Eisai Co. Ltd., Octapharma AG, BioMarin Pharmaceutical Inc., Swedish Orphan Biovitrum AB, Alnylam Pharmaceuticals Inc., Mylan N.V., Clinuvel Pharmaceuticals Ltd., Recordati Rare Diseases Inc.

Global Acute Intermittent Porphyria Market Trends and Insights

Major companies operating in the acute intermittent porphyria market are focused on developing innovative products, such as acute intermittent porphyria management tablets, to serve customers with advanced features better. Acute intermittent porphyria management tablets refer to oral medications used to manage or prevent the symptoms and acute attacks associated with AIP. For instance, in October 2023, Alembic Pharmaceuticals Ltd., an India-based pharmaceutical company, announced the US Food & Drug Administration (USFDA) approval for its Chlorpromazine Hydrochloride Tablets USP, 10 mg, 25 mg, 50 mg, 100 mg, and 200 mg. Chlorpromazine hydrochloride tablets USP, available in doses of 10 mg, 25 mg, 50 mg, 100 mg, and 200 mg, are used to manage the symptoms of psychotic disorders and treat schizophrenia. They also help control nausea and vomiting, alleviate restlessness and apprehension before surgery, and serve as an adjunct in treating tetanus. Additionally, these tablets are utilized in the management of acute intermittent porphyria, control manic symptoms of manic-depressive illness, and provide relief from intractable hiccups.

What Are Latest Mergers And Acquisitions In The Acute Intermittent Porphyria Market?

In April 2024, the American Porphyria Foundation (APF), a US-based non-profit organization, partnered with Recordati Rare Diseases. Through this partnership, the American Porphyria Foundation (APF) aims to raise awareness of porphyria and enhance public understanding and support for AIP. Recordati Rare Diseases is an Italy-based pharmaceutical company treating acute intermittent porphyria (AIP).

What Defines the Acute Intermittent Porphyria Market?

The acute intermittent porphyria market consists of revenues earned by entities by providing services such as genetic testing, clinical consultation, treatment planning and medication management. The market value includes the value of related goods sold by the service provider or included within the service offering. The acute intermittent porphyria market also includes sales of symptom management products, medical devices, nutritional supplements and emergency kits. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Acute Intermittent Porphyria Market Report 2026?

The acute intermittent porphyria market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the acute intermittent porphyria industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.